IgG glycans in health and disease: Prediction, intervention, prognosis, and therapy

Biotechnol Adv. 2023 Oct:67:108169. doi: 10.1016/j.biotechadv.2023.108169. Epub 2023 May 18.

Abstract

Immunoglobulin (IgG) glycosylation is a complex enzymatically controlled process, essential for the structure and function of IgG. IgG glycome is relatively stable in the state of homeostasis, yet its alterations have been associated with aging, pollution and toxic exposure, as well as various diseases, including autoimmune and inflammatory diseases, cardiometabolic diseases, infectious diseases and cancer. IgG is also an effector molecule directly involved in the inflammation processes included in the pathogenesis of many diseases. Numerous recently published studies support the idea that IgG N-glycosylation fine-tunes the immune response and plays a significant role in chronic inflammation. This makes it a promising novel biomarker of biological age, and a prognostic, diagnostic and treatment evaluation tool. Here we provide an overview of the current state of knowledge regarding the IgG glycosylation in health and disease, and its potential applications in pro-active prevention and monitoring of various health interventions.

Keywords: Biological aging; Biomarker; Disease association; Glycosylation; IgG N-glycome; Inflammageing.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Humans
  • Immunoglobulin G*
  • Inflammation
  • Polysaccharides*
  • Prognosis

Substances

  • Immunoglobulin G
  • Biomarkers
  • Polysaccharides